Background Linezolid is a recently approved oxazalidinone with extended activity against
Gram-positive bacteria. We evaluated the results of linezolid therapy in neutropenic cancer …

Background. Gram-positive pathogens can cause serious infections in neutropenic patients
with cancer, and vancomycin therapy is often initiated empirically. Linezolid may offer an …

The increase in serious gram-positive infections has increased the need for treatment of
gram-positive infections in patients with hematologic malignancies. Common gram-positive …

Background Linezolid is the first approved synthetic oxazolidinone with activity against
multidrug-resistant Gram-positive pathogens. However, haematological toxic effects of …

Clinical trials have shown that linezolid (600 mg twice daily in adults) is safe and generally
well tolerated for up to 28 days. Drug-related adverse events, which are typically mild to …

Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through
a compassionate-use program. Patients (n= 796) received 600 mg of linezolid intravenously …

Linezolid has demonstrated activity against antibiotic-susceptible and antibiotic-resistant
aerobic Gram-positive cocci. The availability of intravenous and oral formulations, with near …

We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean
duration, 29±28 days; range, 8 to 185 days) in 44 patients with serious gram-positive …

Linezolid, an oxazolidinone antibiotic, has 100% oral bioavailability and favorable activities
against gram-positive pathogens including multidrug-resistant staphylococci, enterococci …

Objectives Prolonged treatment with linezolid may cause toxicity. The purpose of this study
was to define pharmacodynamic thresholds for improving safety outcomes of linezolid …